These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18183000)

  • 21. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experiences of the drug approval processes in the European Union].
    Pasanen M; Toivonen M
    Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
    [No Abstract]   [Full Text] [Related]  

  • 23. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 25. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 27. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The European Medicines Agency's plans for sharing data from clinical trials.
    Groves T; Godlee F
    BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
    [No Abstract]   [Full Text] [Related]  

  • 29. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. China offers alternative gateway for experimental drugs.
    Jia H; Kling J
    Nat Biotechnol; 2006 Feb; 24(2):117-8. PubMed ID: 16465139
    [No Abstract]   [Full Text] [Related]  

  • 31. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. European Commission takes on Big Pharma.
    den Exter A
    Lancet; 2009 Aug; 374(9690):599-600. PubMed ID: 19699998
    [No Abstract]   [Full Text] [Related]  

  • 33. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 34. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 35. [Organization of the Federal Drug and Medical Products Institute in view of increased European competition].
    Kurth R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Mar; 51(3):340-4. PubMed ID: 18369569
    [No Abstract]   [Full Text] [Related]  

  • 36. A look back at 2000: overabundance and deregulation.
    Prescrire Int; 2001 Apr; 10(52):52-4. PubMed ID: 11718161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMEA tackles "generic" biologic drug issues.
    Rice M
    J Natl Cancer Inst; 2006 Apr; 98(7):435-6. PubMed ID: 16595776
    [No Abstract]   [Full Text] [Related]  

  • 38. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanded EU presents promise and challenges.
    Vermij P
    Nat Rev Drug Discov; 2004 May; 3(5):377-8. PubMed ID: 15152627
    [No Abstract]   [Full Text] [Related]  

  • 40. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.